Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
enoblituzumab plus ipilimumab · 1 trial · 2 indications
Adverse events, serious adverse events
| Arm | Type | Description |
|---|---|---|
| enoblituzumab plus ipilimumab | EXPERIMENTAL | Enoblituzumab: Fc-optimized, humanized monoclonal antibody. Ipilimumab: Yervoy; recombinant, fully humanized IgG-1 CTLA-4 blocking antibody approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of unresectable or metastatic melanoma. |
| Name | Type | Description |
|---|---|---|
| enoblituzumab plus ipilimumab | BIOLOGICAL | enoblituzumab is administered by IV infusion once per week. Ipilimumab is administered by IV infusion every 3 weeks for up to 4 doses. |
Inclusion Criteria - Cohort Expansion Phase: * Histologically-proven, unresectable, locally advanced or metastatic melanoma or NSCLC * Melanoma: Advanced or metastatic melanoma patients may be systemic therapy naïve or may have received systemic treatment for unresectable locally advanced or met...
Top 20 of 51 competitors
Enoblituzumab is an investigational oncology drug being studied for the treatment of neuroblastoma and melanoma. It is also being evaluated in clinical trials for other B7-H3-expressing solid tumors, including non-small cell lung cancer, rhabdomyosarcoma, osteosarcoma, Ewing sarcoma, Wilms tumor, and desmoplastic small round cell tumor.
Enoblituzumab targets B7-H3, a protein expressed on the surface of many solid tumors. By binding to B7-H3, the drug is designed to direct the immune system to attack and destroy cancer cells that express this protein.
Enoblituzumab is developed by MacroGenics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol MGNX.
Enoblituzumab is in Phase 1 clinical development. It is an investigational drug that has not been approved by the FDA and is still being studied in clinical trials.
Enoblituzumab has been studied in two completed Phase 1 clinical trials. NCT02381314 evaluated the drug in combination with ipilimumab in patients with refractory melanoma and non-small cell lung cancer. NCT02982941 evaluated Enoblituzumab as a single agent in children with B7-H3-expressing solid tumors, including neuroblastoma.
Yes, Enoblituzumab is also known as MGA271. The clinical trial NCT02381314 refers to the drug as Enoblituzumab (MGA271), confirming that these names refer to the same investigational agent.